資源描述:
《大肝癌伴門靜脈癌栓病人綜合療法選擇對(duì)照研究-論文.pdf》由會(huì)員上傳分享,免費(fèi)在線閱讀,更多相關(guān)內(nèi)容在應(yīng)用文檔-天天文庫(kù)。
1、中國(guó)實(shí)用外科雜志2014年8月第34卷第8期·757·論著文章編號(hào):1005—2208(2014}08—0757—05DOh10.7504/CJPS.ISSN1005—2208.2014.08.23大肝癌伴門靜脈癌栓病人綜合療法選擇對(duì)照研究吳俁,張志偉,高丹,李常海,董漢華,涂振霄,張貫啟,童兵,陳孝平【摘要】目的分析大肝癌合并門靜脈主干或一級(jí)分支癌栓病人行外科治療并輔以不同綜合治療的療效。方法回顧性分析2003年1月至2010年12月華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬同濟(jì)醫(yī)院經(jīng)影像學(xué)檢查或術(shù)中探查發(fā)現(xiàn)的87例大肝癌合并門靜脈主
2、干或一級(jí)分支癌栓病人的臨床資料。根據(jù)術(shù)后主要抗腫瘤治療方法的不同將病人分為3組:A組,行肝切除+門靜脈取栓術(shù);B組,行肝切除+門靜脈取栓術(shù),術(shù)中留置門靜脈化療泵,術(shù)后行灌注化療;C組,行肝切除+門靜脈取栓術(shù),術(shù)后行肝動(dòng)脈化療栓塞。結(jié)果A、B、C3組的1年總體存活率分別為31.8%、44.7%和49.O%,2年總體存活率分別為12.7%、23.2%和27.2%,3年總體存活率分別為6.4%、11.6%和】1.7%。生存分析顯示:B組存活率高于A組(P:0.049),C組高于A組(尸=0.033),而B組與c組間比較差異無(wú)統(tǒng)
3、計(jì)學(xué)意義(P=O.751)。結(jié)論大肝癌合并門靜脈主干或一級(jí)分支癌栓采用手術(shù)治療同時(shí)術(shù)后行肝動(dòng)脈化療栓塞或門靜脈灌注化療的療效優(yōu)于單純手術(shù)治療,但對(duì)于癌栓累及門靜脈主干的病人仍須慎重選擇手術(shù)治療。【關(guān)鍵詞】肝癌;門靜脈癌栓;肝切除術(shù);肝動(dòng)脈化療栓塞;門靜脈;灌注化療中圖分類號(hào):R6文獻(xiàn)標(biāo)志碼:AComparisonofdiferentcombinedmodalitytherapyaftersurgicaltreatmentoflargeprimarylivercancerwithportalveintumorthrombu
4、sWUYu,ZHANGZhi—wei,GAODan,eta1.HepaticSurgeryCenter,TongjiHospital,TongfiMedicalCollege,HuazhongUniversityofScienceandTechnology,Wuhan430030,ChinaCorrespondingauthor:ZHANGZhi-wei,E-mail:zwzhang@qh.tjmu.edu.cnAbstractObjectiveTostudythevalueofsurgicaltreatmentforl
5、argeprimarylivercancerwithportalveintumorthrombusfPV1involvingthemainorfirst—orderbranches.MethodsTheclinicaldataof87largeprimarylivercancerpatientswithPVTTinvolvingthemainorfirst—orderbranchesunderwenthepatectomyandthrombectomyfromJanuary2003toDecember2010inTong
6、jiHospital,TongjiMedicalCollege,HuazhongUniversityofScienceandTechnologywereanalyzedretrospectively.The87patientsweredividedinto3groups:groupAonlyhavehepatectomyandthrombectomy,groupBhaveportalveininfusionchemotherapyafterhepatectomyandthrombectomy,groupChavetran
7、scatheterhepaticarterialchemoembolizationafterhepatectomyandthrombectomy.ResultsThe1-,2一and3-yearoverallsurvivalrateswere31.8%,12.7%and6I4%forgroupA,44.7%,23.2%and11.6%forgroupBand49.0%,27.2%and11.7%forgroupC.respectively.Theoverallsurvivalsweresignificantlybette
8、ringroupBandgroupCthangroupA(戶l_O.049,P=0.033respectively).TherewasriostatisticalsignificantdifferenceingroupBandgroupC0.7511.ConclusionSurgicalinterventionwit